The uncertainty around the globe — including
decrease in share prices and bond yields, along with the upcoming election — has had an impact on growth in the business travel industry.
Similarly, the dividend yield can vary because of increases or
decreases in the share price.
It was determined that after the strategic review process and corresponding significant
decrease in the share price on the announcement that Fairfax and other institutional investors were investing in the company through a $ 1 billion private placement of convertible debentures, in lieu of purchasing the company, that the carrying value of the company's assets exceeded their fair value based on the impairment testing performed by management.
Conversely, when an investor goes short, he or she is anticipating
a decrease in share price.
Since executive compensation is typically tied to share price, a steep
decrease in the share price is not in a senior management's best interests and therefore dividend cuts are usually a last resort.
The earnings performance would likely translate to increase /
decrease in the share price.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth
in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European countries that may increase the amount of discount required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift
in payer mix to more highly discounted payer segments and geographic regions and
decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market
share and
price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering
prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its
share repurchase program due to changes
in its stock
price, corporate or other market conditions; fluctuations
in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time
in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
For purposes of the offering
in Canada, if all of the
shares have not been sold, after the Canadian underwriters have made a reasonable effort to sell the
shares at the public offer
price, the Canadian underwriters may from time to time
decrease or change the offering
price and the other selling terms provided that the
price for the
shares shall not exceed the public offer
price and further provided that the compensation that is realized by the Canadian underwriters will be
decreased by the amount that the aggregate
price paid by the purchasers for the
shares is less than the gross proceeds paid by the Canadian underwriters to us or the selling stockholders.
Investing
in a volatile and uncertain commodities market may cause a portfolio to rapidly increase or
decrease in value, which may result
in greater
share -
price volatility.
The hedge fund manager seeks to take advantage of the expected increase
in tablet sales — and any corresponding rise
in the tablet company's
share price — while capitalizing on a projected
decrease in desktop sales and any resulting drop
in the desktop maker's stock
price.
If all Base bond holders have been paid but the
price is still too high, the protocol distributes Basecoins to Base
Share holders under the impression they will sell them
in the open market, until the
price decreases back to the target
price.
Evidence clearly shows that for many employee owners their
share price decreased, but not at the levels we saw
in the public stock market.
Investing
in a volatile and uncertain commodities market may cause a portfolio to rapidly increase or
decrease in value which may result
in greater
share price volatility.
Despite an increase
in share price, we've seen a net
decrease in shares outstanding.
The
decrease in dividend from $.24 to $.20 per
share will result
in an annualized distribution rate of approximately 11.2 % using the October 31st closing
price of $ 21.35.
Deutsche Bank upgraded
shares of NovoCure from a «hold» rating to a «buy» rating and
decreased their
price target for the company from $ 23.80 to $ 19.00
in a research note on Thursday, April 19th.
In the event that one or more Authorized Participants having substantial interests in Shares or otherwise responsible for a significant portion of the Shares» daily trading volume on the [EXCHANGE] withdraw from participation, the liquidity of the Shares will likely decrease, which could adversely affect the market price of the Shares and adversely affect an investment in the Share
In the event that one or more Authorized Participants having substantial interests
in Shares or otherwise responsible for a significant portion of the Shares» daily trading volume on the [EXCHANGE] withdraw from participation, the liquidity of the Shares will likely decrease, which could adversely affect the market price of the Shares and adversely affect an investment in the Share
in Shares or otherwise responsible for a significant portion of the
Shares» daily trading volume on the [EXCHANGE] withdraw from participation, the liquidity of the
Shares will likely
decrease, which could adversely affect the market
price of the
Shares and adversely affect an investment
in the Share
in the
Shares.
With improved technology and
decrease in prices, you can use this device which allows for the constant stream of baby watching magic that can be
shared online with anyone you choose to invite or use it at home for quality sleep for parent and baby.
Implementation of reference
pricing was associated with a 7 percent increase
in prescriptions filled for the low -
price reference drug within its therapeutic class, a 14 percent
decrease in average
price paid, and a 5 percent increase
in consumer cost
sharing, the study found.
PR NEWSWIRE - June 6 - First Quarter 2011 Highlights - Income from operations increased 52 % YOY to $ 19.7 M - Adjusted EBITDA increased 33 % YOY to $ 27.2 M - Net loss
decreased from $ 0.60 per
share in 2010 to $ 0.27 per
share in 2011 - Raised $ 50M
in gross proceeds from IPO Q1 2011 Revenue was $ 83.5 M, gross profit was $ 56.8 M. On May 11, 2011, FriendFinder completed its IPO, and issued 5M
shares of common stock at a
price of $ 10.00 per
share.
«What an author gets per copy is not adequate to conclude that they make more money
in total... I don't see any correlation
in the different direction of market
share based on
price increases... Amazon's bestseller list is comprised mostly by low
priced or almost free titles, so it is not fair to conclude that Indy authors make more money by using this sample... more and more of the Big5 publishers have been re-designing their websites to sell ebooks and printed books it could be a reason for the effect into the
decreased market
share that they have on Amazon.»
The forward splits will
decrease the
price per
share of each fund with a proportionate increase
in the number of
shares outstanding.
The return of a mutual fund over N days is the percentage increase (or
decrease)
in the NAV
share price over the N - day period, and the NAV is calculated each evening after the markets have closed and the expense ratio for the day has been subtracted from the fund assets.
On a closing note, there is a weak positive correlation
in most mature industries between stock
price performance and relative
decreases in share count, assets, and sales.
Since stock splits
decrease the stock
price, do they also increase volatility because
shares are traded
in smaller increments?
The stock
price per
share will
decrease; however, the proportionate equity
in the company will remain the same.
In our earlier example of the $ 10,000 purchase of ABC Co. stock, the
price decreased to $ 7 per
share.
Use of leverage tends to magnify increases and
decreases in the Fund's returns and leads to a more volatile
share price.
The reverse splits will increase the
price per
share of each ETF with a proportionate
decrease in the number of
shares outstanding.
On the other hand,
price increase but with
decrease in volume indicates the demand is diminishing for
shares.
Popular among derivative trading, CFDs enable you to speculate on the increase or
decrease in prices of global instruments that include
shares, currencies, indices and commodities.
[Mr. Scott] intends to review his investment
in [ASYS] on a continuing basis and, depending upon the
price and availability of
shares of the Common Stock, subsequent developments affecting [ASYS], [ASYS]'s business and prospects, other investment and business opportunities available to [Mr. Scott], general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to
decrease the size of his investment
in [ASYS].
Finally, what happens if the euro experiences a major depreciation and the company's
share price decreases significantly
in the European market?
When there is an increase
in interest rates, the present value of future dividend payments
decreases, and thus, the
price of a preferred
share would be expected to fall.
This effectively reduces the total number of company
shares in existence, and therefore each
share is worth a larger percentage of the company (and correspondingly, the stock EPS will increase and therefore the P / E will
decrease or the stock
price will go up).
The main source of funding, 2 %
shares of process from CDM, is unlikely to meet the projected financial resources for the fund because the carbon
prices are so volatile: the
price has
decreased from $ 16.39 per tonne
in 2011 to $ 0.82 per tonne of CO2
in 2013.
• The
share of respondents who say home
prices will go up
in the next 12 months
decreased slightly to 48 percent, while the
share who say home
prices will go down
decreased to 5 percent, an all - time survey low.
• The
share of people who say home
prices will go up
in the next 12 months fell slightly to 45 percent, and those who say home
prices will go down
decreased to 9 percent.
At 41 percent, the
share of those surveyed who believe home
prices will go up
in the next 12 months
decreased by 2 percentage points from December's survey high, while the
share who believe home
prices will go down returned to the survey low of 10 percent.